APA (7th ed.) Citation

SEO, K., C, D., L, F., O, C., C, C., C, B., . . . M, T. (2025). Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 43(3), 329. https://doi.org/10.1200/JCO.24.00049

Chicago Style (17th ed.) Citation

SEO, Kacimi, et al. "Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 43, no. 3 (2025): 329. https://doi.org/10.1200/JCO.24.00049.

MLA (9th ed.) Citation

SEO, Kacimi, et al. "Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 43, no. 3, 2025, p. 329, https://doi.org/10.1200/JCO.24.00049.